Investing rewards are a different story. Some of the best investors are contrarians that uncover value by zigging while the ...

Hanesbrands is the market leader in basic innerwear in multiple countries. We believe its key innerwear brands, like Hanes and Bonds in Australia, achieve premium pricing. Our narrow moat rating on ...

We like funds with great long-term performance, but if short-term returns get red hot, we get a little wary. As you may ...

Furthermore, Jacobs’ portfolio is well-aligned with multiple favorable secular trends, including growing investment in infrastructure as well as the transition to clean energy. We believe that Jacobs ...

Nearly 75% of WEC's earnings come from areas with what we view as constructive regulation, such as Wisconsin and at the Federal Energy Regulatory Commission. Its commercial renewable energy business ...

We award a narrow economic moat rating to Femsa based on the intangible assets and cost advantages at major subsidiaries Coca-Cola Femsa and the Oxxo small-format retail chain, which jointly make up ...

The COVID-19 virus may come with a surprising benefit. It may have the ability to shrink certain cancerous tumors, according to a new study.

Scor operates with a dividend policy that is least equal to the dividend paid in the prior year. This is subject to solvency within the 185%-220% target. The dividend can be complemented with share ...

Furthermore, Aecom has improved its profitability thanks to several recent initiatives, including a $225 million general and administrative cost-reduction plan completed in fiscal 2019, real estate ...

In the late 1960s and early 1970s, the so-called Nifty Fifty stocks led big gains for the U.S. market, but ultimately the 1970s was a lost decade for stocks. The late1990s tech boom, led by Microsoft ...

The largest clean energy ETF, the $1.7 billion iShares Global Clean Energy ETF ICLN, has lost 11% since Election Day, while ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...